Our Current Projects

SPECTA is an EORTC pan-European translational research platform, created to promote development of TR projects in Europe, mainly focusing on the biological aspects of cancer, including molecular profiling and personalised therapy.

Currently, there are several projects in progress within the pipeline, each at different stages. The BioRadon project is actively recruiting patients, while the H&N cohort of MRD has recently been activated for recruitment. The IMMUcan, AYA and Arcagen projects are in the final analysis step.

Recruiting

Recruiting

Activation phase

RP-1828 IMMUCAN

Closed to recruitment – Analysis phase

RP-1843 ARCAGEN

Closed to recruitment – Analysis phase

Closed to recruitment – Analysis phase

RP-1920 BIORADON Recruiting
RP-2148-MRD Activation phase
RP-1828 IMMUCAN Closed to recruitment – Analysis phase
RP-1843 ARCAGEN Closed to recruitment – Analysis phase
RP-1759 AYA Closed to recruitment – Analysis phase

Our Projects in the pipeline

In addition to our ongoing projects, we have a pipeline of exciting initiatives currently in pre-development. These projects hold tremendous potential at advancing molecular understanding of cancer, so that clinicians can selectively target specific patient profiles, paving the way for personalised, ‘best fit’ treatments.

To bring these ideas to life, we are seeking financial partners who share our commitment to driving meaningful progress in cancer research. Explore the descriptions below to learn more about each pipeline project and discover how we can collaborate.

If you are interested in developing a project with us, please reach out to specta@eortc.org

2362 SONAR – In pre-development

Project description

Observational study for assessing treatment and outcome of patients with stage III NSCLC. Main objective is to collect high-quality prospective data of all patients diagnosed with stage III NSCLC to characterize disease profiles of interest within this patient population and to further support cancer research.

Our funders

The EORTC study team and coordinators are currently in the process of securing funding to make this important project a reality. The project will commence once the necessary support is in place.

If you are interested in contributing, we invite you to contact the project manager, alexandra.jouret@eortc.org.

Project description

PROTECT is a prospective translational study in patients with cutaneous T-cell lymphoma who receive extracorporeal photochemotherapy as part of routine clinical care. The project will prospectively collect clinical information, treatment and outcome data, and biological samples at predefined timepoints before and during treatment. These samples will be used to investigate immune, tumour-related and molecular changes associated with extracorporeal photochemotherapy. By linking biomarker findings with clinical response and disease evolution, PROTECT aims to improve understanding of the treatment’s mechanisms of action, identify candidate predictors of response or resistance, and support better patient selection and more personalised treatment strategies in cutaneous T-cell lymphoma.

Our funders

The EORTC study team and coordinators are currently in the process of securing funding to make this important project a reality. The project will commence once the necessary support is in place.

If you are interested in contributing, we invite you to contact the study team at SPECTA@eortc.org